Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

CD4+ T cell dysfunction during visceral leishmaniasis

Award Number: R21AI173440
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/10/2022
PERIOD OF PERFORMANCE END DATE: 10/31/2025

Group Awards By:

View Award Description

CD4+ T cell dysfunction during visceral leishmaniasis - PROJECT SUMMARY/ABSTRACT Visceral leishmaniasis is a devastating, neglected tropical disease, ultimately leading to multiorgan failure and death when left untreated. As with many parasitic infections, efforts to develop an effective vaccine have remained unsuccessful. In contrast to a number of infectious pathogens which can be controlled by neutralizing antibodies and/or cytotoxic CD8+ T cells, protection against leishmaniasis is largely mediated by T helper 1 differentiated CD4+ T cells, but how CD4+ T cell activation, differentiation, and function are regulated during visceral leishmaniasis is still largely unknown. A major limitation to these studies has been the inability to accurately identify Leishmania-specific CD4+ T cells in experimental model systems in order to assess T cell longevity and functions during and after the course of the infection. Here, using a recently identified MHC-II epitope conserved across Leishmania species, we show that in contrast to cutaneous versions of leishmaniasis, antigen-specific CD4+ T cells become functionally exhausted during visceral leishmaniasis, produce IL-10, and express high levels of the inhibitory receptors PD-1 and CTLA-4. This suggests that rather than remaining “hidden”, high parasite burden and/or antigen load overwhelms the adaptive immune system to the point where antigen-specific CD4+ T cells lose the capacity to produce the necessary pro-inflammatory cytokines to kill parasites residing within macrophages. Because there is currently no effective vaccine and limited treatment options for leishmaniasis, we have generated recombinant Vaccinia virus (VacV) vectors expressing the immunodominant Leishmania epitope targeted for MHC-II presentation to study the CD4+ T cell response against this parasitic infection. To begin to investigate the mechanisms of CD4+ T cell activation and to identify strategies to reverse or limit T cell dysfunction during visceral leishmaniasis, we will 1) define the functions and gene expression profiles of antigen-specific CD4+ T cells that become activated following either cutaneous or visceral Leishmania infections and 2) determine if therapeutic viral immunization combined with immunotherapy restores function to CD4+ T cells during visceral leishmaniasis. The overall goal of this project will be to begin to define the mechanisms that regulate CD4+ T cell function and dysfunction during visceral leishmaniasis, which will contribute to our long-term goal of improving vaccine design and therapies against this complex parasite.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Allergy and Infectious Diseases Research	000	2	6/2/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $192,500 )
2024	2024	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Allergy and Infectious Diseases Research	000	2	10/26/2023	NON-COMPETING CONTINUATION	$173,250
2024	2024	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Allergy and Infectious Diseases Research	001	2	5/10/2024	NON-COMPETING CONTINUATION	$19,250
														Subtotal = $192,500

Issue Date FY: 2023 ( Subtotal = $231,000 )
2023	2023	OREGON HEALTH & SCIENCE UNIVERSITY	3181 SW SAM JACKSON PARK RD	PORTLAND	OR	97239	MULTNOMAH	USA	Allergy and Infectious Diseases Research	000	1	11/10/2022	NEW	$231,000
														Subtotal = $231,000

Grand Total All Awards = $423,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CD4+ T cell dysfunction during visceral leishmaniasis

Award Number: R21AI173440

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/10/2022

PERIOD OF PERFORMANCE END DATE: 10/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer